A citation-based method for searching scientific literature

Peter Priestley, Jonathan Baber, Martijn P Lolkema, Neeltje Steeghs, Ewart de Bruijn, Charles Shale, Korneel Duyvesteyn, Susan Haidari, Arne van Hoeck, Wendy Onstenk, Paul Roepman, Mircea Voda, Haiko J Bloemendal, Vivianne C G Tjan-Heijnen, Carla M L van Herpen, Mariette Labots, Petronella O Witteveen, Egbert F Smit, Stefan Sleijfer, Emile E Voest, Edwin Cuppen. Nature 2019
Times Cited: 354



D L van der Velden, L R Hoes, H van der Wijngaart, J M van Berge Henegouwen, E van Werkhoven, P Roepman, R L Schilsky, W W J de Leng, A D R Huitema, B Nuijen, P M Nederlof, C M L van Herpen, D J A de Groot, L A Devriese, A Hoeben, M J A de Jonge, M Chalabi, E F Smit, A J de Langen, N Mehra, M Labots, E Kapiteijn, S Sleijfer, E Cuppen, H M W Verheul, H Gelderblom, E E Voest. Nature 2019
Times Cited: 89




List of shared articles



Times cited

Clinical utility of whole-genome sequencing in precision oncology.
Richard Rosenquist, Edwin Cuppen, Reinhard Buettner, Carlos Caldas, Helene Dreau, Olivier Elemento, Geert Frederix, Sean Grimmond, Torsten Haferlach, Vaidehi Jobanputra,[...]. Semin Cancer Biol 2022
9

Healthcare policy by other means: Cancer clinical research as "oncopolicy".
Alberto Cambrosio, Jonah Campbell, Peter Keating, Jessica B Polk, Adriana Aguilar-Mahecha, Mark Basik. Soc Sci Med 2022
0

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.
Louisa R Hoes, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J Zeverijn, Daphne L van der Velden, Joris van de Haar, Paul Roepman, Wendy J de Leng, Anne M L Jansen, Erik van Werkhoven,[...]. Clin Cancer Res 2022
4

Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.
Denis Horgan, Giuseppe Curigliano, Olaf Rieß, Paul Hofman, Reinhard Büttner, Pierfranco Conte, Tanja Cufer, William M Gallagher, Nadia Georges, Keith Kerr,[...]. J Pers Med 2022
9

Delivering precision oncology to patients with cancer.
Joaquin Mateo, Lotte Steuten, Philippe Aftimos, Fabrice André, Mark Davies, Elena Garralda, Jan Geissler, Don Husereau, Iciar Martinez-Lopez, Nicola Normanno,[...]. Nat Med 2022
21

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
J M van Berge Henegouwen, H van der Wijngaart, L J Zeverijn, L R Hoes, M Meertens, A D R Huitema, L A Devriese, M Labots, H M W Verheul, E E Voest,[...]. Cancer Chemother Pharmacol 2022
0

Whole-genome and transcriptome analysis enhances precision cancer treatment options.
E Pleasance, A Bohm, L M Williamson, J M T Nelson, Y Shen, M Bonakdar, E Titmuss, V Csizmok, K Wee, S Hosseinzadeh,[...]. Ann Oncol 2022
3

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
J M van Berge Henegouwen, M Jebbink, L R Hoes, H van der Wijngaart, L J Zeverijn, D L van der Velden, P Roepman, W W J de Leng, A M L Jansen, E van Werkhoven,[...]. Eur J Cancer 2022
1